FilingReader Intelligence

Zhejiang Hisoar Pharmaceutical updates on share repurchase progress

October 9, 2025 at 08:41 AM UTCBy FilingReader AI

Zhejiang Hisoar Pharmaceutical announced the latest progress of its share repurchase plan, initially approved by the board on April 9, 2025. The company intends to repurchase its shares using its own or self-raised funds through centralized bidding, allocating between RMB 150 million and RMB 300 million for the program, with a maximum repurchase price of RMB 7.46 per share. This repurchase is intended for future equity incentives or employee stock ownership plans.

As of September 30, 2025, Zhejiang Hisoar Pharmaceutical has cumulatively repurchased 4,410,000 shares through the Shenzhen Stock Exchange, representing 0.27% of its total share capital. The repurchases were executed at prices ranging from a low of RMB 5.66 per share to a high of RMB 6.29 per share. The total transaction value, excluding trading fees, amounted to RMB 26,090,960.52.

The company confirms that the repurchases comply with all relevant laws, regulations, and the established repurchase plan. Zhejiang Hisoar Pharmaceutical will continue to implement the repurchase plan within the designated period and will provide timely disclosures of progress, adhering to regulatory requirements.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

News Alerts

Get instant email alerts when Zhejiang Hisoar Pharmaceutical publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →